Business Daily from THE HINDU group of publications
Monday, Nov 02, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
Business Daily from THE HINDU group of publications Monday, Nov 02, 2009 ePaper | Mobile/PDA Version | Audio | Blogs |
|
|
|
|
|
Corporate Results
-
Pharmaceuticals Suven Life Q2 net dips 48% to Rs 2.5 cr Our Bureau Hyderabad, Nov. 1 Suven Life Sciences Ltd’s net profit decreased 48 per cent at Rs 2.5 crore in the second quarter ended September 30 compared with Rs 4.8 crore in the corresponding quarter of the previous financial year. The revenue of the Hyderabad-based company declined 14 per cent at Rs 33.2 crore (Rs 38.6 crore). The earnings per share stood at Rs 0.22 (Rs 0.42), it said in a release. “The decrease in earnings was largely due to decline in revenues and increase in R&D expenses,” Mr Venkat Jasti, Chairman and CEO, told Business Line. Suven continued its thrust on R&D by spending Rs 17.2 crore for the half-year ended September 30. The company’s drug discovery pipeline consists of 10 molecules on six targets in central nervous system arena which were at various stages of discovery and development. “Out of the 10 molecules, SUVN 502 is a lead clinical candidate which has successfully finished Phase-I clinical trial and currently undergoing bridge toxicology studies. This would enable the molecule to move into proof of concept stage in 2010,” he said. Suven Life secures 2 US patents Suven gets first milestone payment from Eli Lilly Suven Life Sciences Q1 net up 36% More Stories on : Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2009, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|